Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Pediatr Blood Cancer. 2020 Sep 4;67(11):e28647. doi: 10.1002/pbc.28647

Figure 2: Proportion of institutions incorporating expanded audiometry into clinical decision making.

Figure 2:

Depiction of how responding sites currently factor into clinical decision making for cisplatin dosing the results from expanded audiometric testing such as high frequency audiometry (HFA, >8,000 Hz), distortion-product otoacoustic emissions (DPOAE), and speech audiometry (SA).